| Cardiovascular disease(CVD) is a very serious disease harmfulto the health of the mankind.IN recent years,no matter in westencountry or easten country,the morbility and mortality rate of thiskind of disease have significant increasing tendency, and thisdisease gradually became the first killer of the life of people.Withthe development of medical science, people realized that the higherlevel of the cholesterol and fat is the basic cause of thecardiovascular disease;and hyperlipemia is the main risk leadingto coronary heart disease(CHD) and hypertension.So, the developingof the medicine of regulating blood-fat is the emphasis of theprevention and cure of CVD.From 1980's,many lipid-lowing drugs werebrought out,and stains received high praise among them.The excellentclinical therapeutic effect is imcomparable with other kinds,therefore ,the research and exploitation of stains is constantly thehot spot of people's attention. Rosuvastatin which we selected inthis experiment,is the second generation newest stains.It has agood quality of decreasing the level of LDL-C and increasing the levelof HDL-C, accordingly, reducing the incidence of cardiovascularevents. presently, rosuvastatin hasn't gone to the market yet.Objective:This clinical trial was designed to assess the lipidsregulating effects and safety of domestic rosuvastatin versussimvastatin.factory as controll group, adopting randomized double-blinddouble-imitated parallel controlled design, 53 patients qualifiedfor the test were randomly into 3 group A,B,C.There were 18 patientsin group A and B,and 17 ones in group C.(A=rosuvastatin 5mg, B=rosuvastatin 10mg, C=simvastatin20mg),and take orally the medicinefor 8 weeks continuously.The tablets should be taken once in everyevening before go to bed or three hours after supper.Moreover, eachpatient must keep the same diet and living habit. All the patientswere followed up at the 4th week and 8th week, receiving theobservation and comparison of the therapeutic and adverseeffect,then the data was dealt with statistics.Results: 53 patients finished the trial altogether.one case fell offbecause of the bad cooperation. At the 4th week,serum totalcholesterol(TC) in group A , B and C decreased by 27.48%,23.75%,19.89%;serum triglyecerides(TG) decreased by 54.75%,47.47%,54.24%;and serum LDL-C decreased by 36.54%,35.80%,28.64%;there was nosignificant difference between the three groups (P>0.05).SerumHDL-C increased by 14.56%,34.00% ,22.86% , there was significantdifference between group A , B(P<0.05), group C and B,A had nosignificant differences respectively (P>0.05)。At the 8th week,serumtotal cholesterol(TC) in group A , B and C decreased by 23.58%,23.93%,17.84% ,and serum triglyecerides(TG) decreased by 51.15%,54.75%,60.34%;serum LDL-C decreased by 30.12%,40.49% ,28.90% ,therewas no significant difference between the three groups(P>0.05).serum HDL-C increased by 10.00%,44.00%和8.89%, there wassignificant difference between group A , B(P<0.05), group C and B,A had no significant difference respectively (P>0.05)。Except forHDL–C in group A, all changeable percentages at 4th or 8th week oftrial had significant difference compared with pretrial ones(P<0.05).And The clinical effects were no more significant at the 8th weekthan at the 4th week to three groups(P>0.05). The incidence of sideeffects in the three groups was similar(P>0.05).Conclusions: The clinical effects of rosuvastatin is exact andsafe,and it is worthy of applying for the clinical treatment. |
PDF Full Text Request